|
|
Post by myocat on Dec 19, 2020 10:59:39 GMT -5
It's been over a year since Biomm and Mannkind signed sale and distribution agreement. I wonder if we see any sale figure in this coming qtr CC. Anyone knows?  ? |
|
|
|
Post by matt on Dec 19, 2020 11:18:59 GMT -5
The company is required to report geographic segment sales in the 10K so yes, you will see the full year sales to Biomm if you read the footnote disclosures. Most companies do not report international sales separately on a quarterly basis unless the number is a material part of the overall company results as there is no requirement to report geographic segments in quarterly reports (i.e. quarterly reporting is optional, annual reporting is required).
|
|
|
|
Post by kite on Dec 22, 2020 18:12:58 GMT -5
Like news segments and articles we've seen in the US about Afrezza (although its been a while), I wonder if Afrezza has been featured on the news in Brazil since the launch...
|
|
|
|
Post by longliner on May 6, 2021 16:47:25 GMT -5
www.clinicaltrialsarena.com/news/cytodyn-aeih-trials-leronlimab/Last month, CytoDyn and Biomm signed an exclusive supply and distribution agreement that will enable the latter to market leronlimab in Brazil on receiving regulatory approval. I would love to see some collaboration with Mannkind regarding leronlimab through Biomm. It appears both CytoDyn and Mannkind are now partnered with Biomm.
|
|
|
|
Post by patten1962 on Jun 30, 2021 22:15:31 GMT -5
Anything New with Mannkind and Brazil?
|
|
|
|
Post by mnkdfann on Jun 30, 2021 23:38:28 GMT -5
Anything New with Mannkind and Brazil? Not exactly new, but sorta newish ... According to the 10K filed on February 25, 2021: investors.mannkindcorp.com/static-files/c200a41e-04e9-4e86-a7d7-c74d7d1e237f Revenue from collaborations and services for the years ended December 31, 2020 and 2019 are as follows (in thousands): Biomm Distribution Agreement: 2020 2019 - 75 Biomm Supply and Distribution Agreement – In May 2017, the Company and Biomm entered into a supply and distribution agreement for the commercialization of Afrezza in Brazil. Under this agreement, Biomm was responsible for pursuing regulatory approvals of Afrezza in Brazil, including from the Agência Nacional de Vigilância Sanitária (“ANVISA”) and, with respect to pricing matters, from the Camara de Regulação de Mercado de Medicamentos (“CMED”), both of which have now been received. Biomm commenced product sales in January 2020. In September 2019, the Company delivered its first shipment of Afrezza to Biomm and recorded it as net revenue — commercial product sales for $0.7 million, in advance of the planned launch of the product in Brazil by Biomm. During the second quarter of 2020, the Company sold $0.2 million of product to Biomm. No additional shipments were made in 2020. |
|
|
|
Post by patten1962 on Jul 1, 2021 6:03:09 GMT -5
Anything New with Mannkind and Brazil? Not exactly new, but sorta newish ... According to the 10K filed on February 25, 2021: investors.mannkindcorp.com/static-files/c200a41e-04e9-4e86-a7d7-c74d7d1e237f Revenue from collaborations and services for the years ended December 31, 2020 and 2019 are as follows (in thousands): Biomm Distribution Agreement: 2020 2019 - 75 Biomm Supply and Distribution Agreement – In May 2017, the Company and Biomm entered into a supply and distribution agreement for the commercialization of Afrezza in Brazil. Under this agreement, Biomm was responsible for pursuing regulatory approvals of Afrezza in Brazil, including from the Agência Nacional de Vigilância Sanitária (“ANVISA”) and, with respect to pricing matters, from the Camara de Regulação de Mercado de Medicamentos (“CMED”), both of which have now been received. Biomm commenced product sales in January 2020. In September 2019, the Company delivered its first shipment of Afrezza to Biomm and recorded it as net revenue — commercial product sales for $0.7 million, in advance of the planned launch of the product in Brazil by Biomm. During the second quarter of 2020, the Company sold $0.2 million of product to Biomm. No additional shipments were made in 2020. Thank you very much. This is not a home run but for sure it's a start! Any sales is better than no sales. Wondering if our Medicare News will somehow open some eyes in Brazil? Thanks again! |
|
|
|
Post by peppy on Jul 1, 2021 6:09:38 GMT -5
Not exactly new, but sorta newish ... According to the 10K filed on February 25, 2021: investors.mannkindcorp.com/static-files/c200a41e-04e9-4e86-a7d7-c74d7d1e237f Revenue from collaborations and services for the years ended December 31, 2020 and 2019 are as follows (in thousands): Biomm Distribution Agreement: 2020 2019 - 75 Biomm Supply and Distribution Agreement – In May 2017, the Company and Biomm entered into a supply and distribution agreement for the commercialization of Afrezza in Brazil. Under this agreement, Biomm was responsible for pursuing regulatory approvals of Afrezza in Brazil, including from the Agência Nacional de Vigilância Sanitária (“ANVISA”) and, with respect to pricing matters, from the Camara de Regulação de Mercado de Medicamentos (“CMED”), both of which have now been received. Biomm commenced product sales in January 2020. In September 2019, the Company delivered its first shipment of Afrezza to Biomm and recorded it as net revenue — commercial product sales for $0.7 million, in advance of the planned launch of the product in Brazil by Biomm. During the second quarter of 2020, the Company sold $0.2 million of product to Biomm. No additional shipments were made in 2020. Thank you very much. This is not a home run but for sure it's a start! Any sales is better than no sales. Wondering if our Medicare News will somehow open some eyes in Brazil? Thanks again! Brazil is being ravaged by SARS2 COVID-19. The population is being reduced. |
|
|
|
Post by patten1962 on Jul 1, 2021 7:16:51 GMT -5
Thank you very much. This is not a home run but for sure it's a start! Any sales is better than no sales. Wondering if our Medicare News will somehow open some eyes in Brazil? Thanks again! Brazil is being ravaged by SARS2 COVID-19. The population is being reduced. Hi Peppy. Hope all is well. My following comments, I am not being confrontational. 1. How do we know Brazil is really being ravaged? My ex lived in Brazil and we have many friends still there. Not what we hear. 2. 5% of the population will test positive for Covid during "Non Pandemic Times". 3. Even if Covid is still bad in Brazil, people with Diabetes will still need Afrezza. 4. I work in a very large hospital outside of Chicago, for the last year very few Covid deaths. And the Deaths we have had,people had other comorbidities. |
|
|
|
Post by peppy on Jul 1, 2021 7:26:18 GMT -5
Brazil is being ravaged by SARS2 COVID-19. The population is being reduced. Hi Peppy. Hope all is well. My following comments, I am not being confrontational. 1. How do we know Brazil is really being ravaged? My ex lived in Brazil and we have many friends still there. Not what we hear. 2. 5% of the population will test positive for Covid during "Non Pandemic Times". 3. Even if Covid is still bad in Brazil, people with Diabetes will still need Afrezza. 4. I work in a very large hospital outside of Chicago, for the last year very few Covid deaths. And the Deaths we have had,people had other comorbidities. Hello patten, always nice to see you. |
|
|
|
Post by mango on Jul 1, 2021 7:29:32 GMT -5
The evidence for Ivermectin is outstanding. Ironic how the alphabet agencies aren’t recommending it despite the evidence and proven safety. It’s off patent (so no money to be made) yet push push push vaccines like there’s no tomorrow only because there’s billions to be made, despite the horrific side effects and adverse events, limited preclinical and clinical studies and so on.
COVID-19 could very well become extinct with ivermectin therapy and using it prophylactically.
|
|
|
|
Post by olderteampt on Jul 1, 2021 8:03:35 GMT -5
Mango I could not agree with you more. I have worked in the medical field for over 26 years and people need to ignore what the paid TV ads say, ignore what their paid phone ads say and ignore what the paid radio ads say and do the real research for themselves. Take the time to read the research and go back 10 to 20 years on: what masks can and can not block, what the ivermectin studies say and what the hydroxychloroquine studies say. When you are done ask yourself when it comes to your health should you follow the Money or what Science says?
|
|
|
|
Post by mango on Jul 1, 2021 9:17:52 GMT -5
Mango I could not agree with you more. I have worked in the medical field for over 26 years and people need to ignore what the paid TV ads say, ignore what their paid phone ads say and ignore what the paid radio ads say and do the real research for themselves. Take the time to read the research and go back 10 to 20 years on: what masks can and can not block, what the ivermectin studies say and what the hydroxychloroquine studies say. When you are done ask yourself when it comes to your health should you follow the Money or what Science says? This same principle of thinking and evaluating the available evidence (which also includes real-life evidence outside the lab and clinical trials) can be applied to diabetes treatments and Afrezza. For example, we have known for decades now that people with T2D have a loss of the first-phase insulin response and need their post-meal spike corrected. Instead of deploying a mealtime insulin that matches physiologic insulin and restores the first-phase, The Establishment endorses a dangerous treat-to-fail protocol involving agents that do not address the underlying defect and only apply a bandaid at best to the problem. Furthermore, we elect to basal insulin for T2D (and even before prandial insulin) which is medically incorrect. It is clear that the pay-to-play game in medicine is in full force. |
|
|
|
Post by lazyb767 on Jul 1, 2021 9:42:07 GMT -5
The evidence for Ivermectin is outstanding. Ironic how the alphabet agencies aren’t recommending it despite the evidence and proven safety. It’s off patent (so no money to be made) yet push push push vaccines like there’s no tomorrow only because there’s billions to be made, despite the horrific side effects and adverse events, limited preclinical and clinical studies and so on. COVID-19 could very well become extinct with ivermectin therapy and using it prophylactically. YouTube crushed/censored the original presentation by Weinstein and guests. They broke he presentation down into snippets… |
|
|
|
Post by mango on Jul 1, 2021 10:08:38 GMT -5
The evidence for Ivermectin is outstanding. Ironic how the alphabet agencies aren’t recommending it despite the evidence and proven safety. It’s off patent (so no money to be made) yet push push push vaccines like there’s no tomorrow only because there’s billions to be made, despite the horrific side effects and adverse events, limited preclinical and clinical studies and so on. COVID-19 could very well become extinct with ivermectin therapy and using it prophylactically. YouTube crushed/censored the original presentation by Weinstein and guests. They broke he presentation down into snippets… The podcasts with Weinstein on Lex Friedman and also on Joe Rogan (both solo and accompanied by pulmonologist and ivermectin expert Dr. Pierre Kory, MD) are very informative, especially in the wake of folks who originally dismissed the hypothesis that COVID-19 leaked from the Wuhan lab, or some other lab, starting to actually examine the evidence and change their tune. The censorship is disgusting. |
|
?
